問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chung Shan Medical University Hospital (在職)

Division of Rheumatology

Division of General Internal Medicine

Division of Dermatology

更新時間：2023-09-19

魏正宗
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

35Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

魏正宗

Chung Shan Medical University Hospital

Division of Rheumatology

List

52Cases

2021-07-09 - 2026-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2016-08-01 - 2020-12-31

Phase I

A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 versus EU sourced MabThera® in Anti TNF Inadequate Responder Patients with Moderate to Severe RA on Background MTX Therapy

  • Condition/Disease

    Rheumatoid Arthritis (RA)

  • Test Drug

    JHL1101

Participate Sites
3Sites

Terminated3Sites

2013-04-01 - 2022-12-05

Phase IV

A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, AutoantibodyPositive Systemic Lupus Erythematosus Receiving Belimumab

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    BENLYSTA (Belimumab)

Participate Sites
8Sites

Recruiting1Sites

Terminated7Sites

黃春明
China Medical University Hospital

2012-04-01 - 2013-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2008-07-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2012-02-01 - 2016-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2011-10-01 - 2012-11-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2018-11-01 - 2022-06-21

Phase III

A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients with Rheumatoid Arthritis (RA) who Had an Inadequate Response or Intolerance to MTX

  • Condition/Disease

    Rheumatoid Arthritis (RA)

  • Test Drug

    ASP015K

Participate Sites
6Sites

Terminated5Sites

黃春明
China Medical University Hospital-Taipei

未分科

張棋楨
Taipei Medical University Hospital

2009-06-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated1Sites

Study ended4Sites

2012-11-05 - 2015-12-31

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs with Moderately to Severely Active Rheumatoid Arthritis

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
11Sites

Terminated10Sites

Study ended1Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB